Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country.
Saved in:
| Title: | Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country. |
|---|---|
| Authors: | Do, Thang Xuan1 (AUTHOR), Nguyen, Ha Thi2 (AUTHOR) nthiha@uhsvnu.edu.vn, Nguyen, Phuong Thi Lan2 (AUTHOR), Kieu, Mai Thi Tuyet1 (AUTHOR), Duong, Tuan Viet1 (AUTHOR), Pham, Van Nu Hanh1 (AUTHOR) |
| Source: | PLoS ONE. 4/3/2026, Vol. 21 Issue 4, p1-13. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
